arrow
K

Ki-Seong Eom

seoul st. mary's hospital
H指数:30
被引数:3,443

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Feasibility of a Total Body Irradiation-Augmented Reduced-Toxicity Conditioning Regimen with an Antithymocyte Globulin/Post-Transplantation Cyclophosphamide Combination for Haploidentical Donor Transplantation in Adult Acute Lymphoblastic Leukemia

异基因供者移植中成人急性淋巴细胞白血病采用抗胸腺细胞球蛋白/移植后环磷酰胺联合方案增敏的全身体外照射增强减毒预处理方案的安全性评估

2025-05-240
PRE
Real-World Wutcome of Defibrotide for Treatment of Adult Patients Who Developed Severe Hepatic VOD/SOS after Allogeneic Hematopoietic Cell Transplantation

异基因造血细胞移植后发生严重肝静脉闭塞病/窦状隙梗阻综合征的成年患者使用Defibrotide治疗的真实世界结局

BLOOD
IF23.1
2024-11-050
PRE
Real-World Experience of Blinatumomab for 8 Years Regarding Predictive Factors Including Lymphocyte Kinetics for Response and Survival Outcome in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia

真实世界经验:Blinatumomab在成人复发或难治性急性淋巴细胞白血病中关于包括淋巴细胞动力学在内的预测因素对反应和生存结局的8年经验

BLOOD
IF23.1
2024-11-050
PRE
Efficacy of ex vivo purging with CD34+selection to maximize the effects of autologous stem cell transplantation in peripheral T-cell lymphoma patients

CD34选择体外净化最大化自体干细胞移植在外周T细胞淋巴瘤患者中的疗效

2023-12-010
OAAI
A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML)

复发/难治性急性髓系白血病 (AML) 患者的挽救性强化化疗与维尼托克联合方案的回顾性比较

2022-03-239
OAAI